We have examined the ligand regulation and G protein selectivity of the human cannabinoid CB 1 and CB 2 receptors by an in situ reconstitution technique directly measuring G protein activation. Membranes from Spodoptera frugiperda cells expressing CB 1 and CB 2 receptors were chaotrope extracted to denature endogenous GTP-binding proteins. The ability of the receptors to catalyze the GDP-GTP exchange of each G protein was then examined with purified bovine brain G i and G o . Activation of CB 1 receptors produced a high-affinity saturable interaction for both G i and G o . Agonist stimulation of CB 2 receptors also resulted in a high-affinity saturable interaction with G i . In contrast, CB 2 receptors did not interact efficiently with G o . G protein activation was then examined with a diverse group of ligands. For the interaction of CB 2 receptors with G i , HU210 was the only compound tested that demonstrated maximal activation. In contrast, WIN55,212 (64%), anandamide (42%), and ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC) (44%) all initiated submaximal levels of G protein activation. For CB 1 receptor-catalyzed activation of G i , HU210, WIN55,212, and anandamide all elicited maximal activation, whereas ⌬ 9 -THC (56 Ϯ 6%) caused only partial G i activation. In contrast, only HU210 effected maximal CB 1 stimulation of G o , with anandamide, WIN55,212, and ⌬ 9 -THC all stimulating between 60 and 75% compared with HU210. These data demonstrate that different agonists induce different conformations of the CB 1 receptor, which in turn can distinguish between different G proteins. Our data thus demonstrate agonist-selective G protein signaling by the CB 1 receptor and suggest that therapeutic agents may be designed to regulate individual G protein-signaling pathways selectively.
selective cannabinoid stimulation of multiple G protein-coupled pathways is attractive, it remains untested.
We have recently developed an approach to the investigation of receptor-G protein coupling that enables precise characterization of the coupling properties of the receptors to individual G protein subtypes (Hartman and Northup, 1996) . Our technique uses recombinant expressed receptors in situ in membrane fractions from which extrinsic membrane proteins have been removed or inactivated by urea extraction. Although depleted of G protein, the uncoupled receptors remain fully functional for reconstitution with purified G protein subunits. The depletion of endogenous G proteins from the membrane enables the controlled addition of isolated G proteins for analysis. In addition to depleting endogenous G proteins, the urea washing removes or destroys nonintegral membrane proteins, including small GTP-binding proteins, greatly reducing the GTP-binding capacity of the membranes and enhancing the signal from reconstituted G proteins. This technique has previously been successfully used to characterize receptor-G protein interactions of the 5-hydroxytryptamine (5-HT) 2c (serotonin) receptor (Hartman and Northup, 1996) , and the bombesin family of receptors (Jian et al., 1999) with G q . However, the high intrinsic rate of GDP-GTP exchange has inhibited its application for receptors coupled to G i/o . To overcome this technical obstacle, we have adapted our procedures to suppress the spontaneous binding signal and to require the exchange to be receptor catalyzed.
In this study, we have examined the ability of the human CB 1 and CB 2 receptors expressed in Spodoptera frugiperda cells (Sf9) to catalyze the activation of the pertussis toxinsensitive G proteins G i and G o . In situ reconstitution of CB 1 receptors reveals G protein-selective agonist efficacies of cannabinoid ligands. S]GTP␥S (specific activity, 1100 -1200 Ci/mmol) was purchased from NEN (Boston, MA). cDNA for the human CB 1 receptor was received from Dr. T. Bonner (National Institute of Mental Health, Bethesda, MD), and for the human CB 2 receptor was from Dr. S. Munro (Cambridge, UK). All other compounds were purchased from Sigma Chemical Co. (St. Louis, MO). Membranes Preparation and Urea Extraction. Sf9 cells in suspension were infected with either CB 1 receptor or CB 2 receptor virus at a multiplicity of infection of ϳ4. The cells were harvested 48 h postinfection by sedimentation at 500 rpm for 5 min in a Hereaus megafuge 2.0. After one wash in PBS, the cells were resuspended into solution A [10 mM 4-morpholinepropanesulfonic acid (MOPS), pH 7.5, 1 mM EGTA,100 M 4-(2-aminoethyl)benzenesulfonyl fluoride] and left at 4°C for 30 min before cell lysis with a Dounce homogenizer. Nuclei and cell debris were removed by centrifugation at 1600g for 10 min in a Hereaus megafuge 2.0, and the postnuclear fraction (P2) was collected at 40,000g for 30 min in a Beckman JA-20 rotor and J2-21 centrifuge. The P2 membrane pellet was suspended in ice-cold solution A containing 7 M urea. After incubation with urea for 30 min on ice, the membrane solution was diluted to Ͻ4 M urea with solution A and then sedimented at 142,000g for 30 min at 4°C in a Beckman 45Ti rotor and L8-70 M ultracentrifuge. The membrane pellet was then washed once with solution A and collected by sedimentation as before. The final pellet was suspended in solution A with 200 mM sucrose, and aliquots were snap frozen and stored at Ϫ80°C.
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Formation
Quantification of Receptor Sites. Binding site abundance was determined by saturation-binding assay with 0.1 to 30 nM
Binding reactions were performed for 1 h at 30°C in solution B (50 mM Tris, pH 7.5, 3 mM MgCl 2, 1 mM EDTA) and 5 mg/ml fraction V BSA in a final reaction volume of 300 l containing 10 to 40 g of membrane protein. The incubation was terminated by addition of 2.5 ml of ice-cold solution B, and samples were filtered through Whatman GF-C filters and washed with 2.5 ml of solution B. Filters were then soaked in 400 l of 2% SDS for 2 h before the addition of 10 ml of Cytoscint (ICN Pharmaceuticals, Costa Mesa, CA) scintillation fluid. The filters were soaked in Cytoscint for at least 5 h before analysis by liquid scintillation spectometry in a Wallac 1219 beta counter.
Purification of G Protein Subunits. G proteins G i , G o , and ␤␥-subunits were isolated from bovine cortex following a previously published protocol (Sternweis and Robinshaw, 1984; Mumby et al., 1988) . Due to the apparent instability of G␣ i in the absence of ␤␥, G i was maintained as a trimer. Immunological analysis by Western blot indicated that the G i sample contained G␣ i-1 -, G␣ i-2 -, and G␣ i-3 -subunits. Squid G␣ q (Hartman and Northup, 1996) and bovine retinal G␣ t (Fawzi and Northup, 1990) were purified following previously published protocols. After purification, all subunits were eluted over a G 50 column to ensure the final solution concentration for ␣-subunits was 10 mM MOPS, pH 7.5, 1 mM MgCl 2 , and 4 mM 3-[(3-cholamidopropyl)dimethylamminio]propanesulfonate, and for ␤␥ was 10 mM MOPS, pH 7.5, 100 mM NaCl 2 , and 8 mM 3-[(3-cholamidopropyl)dimethylamminio]propanesulfonate. G␣-subunit concentration assay was assessed by [ 35 S]GTP␥S binding in the presence of 1 M GTP␥S for up to 2 h in a solution containing 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 11 mM MgCl 2 , and 0.1% lubrol (Northup et al., 1982) . Reactions were terminated by the addition of 2.5 ml of solution D (20 mM Tris-HCl, pH 8.0, 25 mM MgCl 2 , and 100 mM NaCl) and filtered over nitrocellulose membranes on a Millipore vacuum manifold. The filters were washed four times with 2.5 ml of ice-cold solution D, dried, and the bound radioactivity was counted by liquid scintillation in a Wallac 1219 beta counter.
Reconstitution Agonist Saturation Analysis. Agonist saturation analysis were determined for all receptor-G protein high-affinity interactions (CB 1 with G i and G o ; CB 2 with G i only). Experiments were performed at approximate K m values (20 nM G␣ i or 80 nM G␣ o ) and saturating ␤␥ (100 nM), with 3 to 10 nM CB 1 or CB 2 receptor. Membranes were preincubated with agonist for 10 min at 30°C before the addition of [ 35 S]GTP␥S containing reaction mixture. The reaction was allowed to proceed for an additional 10 min before termination and filtration as described above. Affinity constants for the agonist catalyzed GDP-[ 35 S]GTP␥S exchange were calculated with nonlinear regression analysis for a sigmoidal dose response with GraphPad Prism.
Inverse Agonism of SR141716A at CB 1 Receptor. To test for inverse agonism of the CB 1 receptor, 10 g of urea-washed membranes was incubated with 80 nM G␣ o or 20 nM G␣ i and saturating ␤␥ in a modified solution C (10 mM MOPS, pH 7.5, 100 mM NaCl, 6 mM MgCl 2 , 1 mM EDTA, 5 mg/ml BSA, 4 M GDP, and ϳ0.4 nM [ 35 S]GTP␥S) in the presence and absence of 1 M SR141716A. The reaction proceeded for 10 min at 30°C before termination and filtration as described above.
Results
Reconstitution of Cannabinoid Receptors with G Protein Subunits. Sf9 cells infected with either the human CB 1 or CB 2 receptor-encoding baculoviruses were harvested 48 h after infection, and were urea-washed. Binding assays with the antagonists SR141716A (CB 1 ) and SR144528 (CB 2 ) demonstrated high-affinity binding to a single site in both cases. Baculovirus expression of CB 1 or CB 2 receptors resulted in membranes expressing ϳ15 and 33 pmol/mg, respectively. The conditions for the reconstitution experiments were optimized to decrease the rates of the noncatalyzed [ 35 S]GTP␥S-binding reactions performed in this way were consistent with a ligand-regulated rate constant proportional to the added CB 1 or CB 2 receptor (data not shown). Furthermore, no cannabinoid ligand regulation of the rate of binding was observed in the absence of expressed CB 1 or CB 2 receptor (data not shown).
As demonstrated in Fig. 1, a and 39.7 Ϯ 3.6 nM (CB 2 ) (mean Ϯ S.E.; n ϭ 3).
The activation of G␣ o by CB 1 and CB 2 receptors is shown in Fig. 2 , a and c. The CB 1 and CB 2 receptors demonstrate low catalysis of G␣ o activation in the absence of agonist. Addition of HU210 resulted in a significant increase in G protein activation for both CB 1 and CB 2 receptors. In contrast to the nearly identical interaction of G␣ i with these receptors, G␣ o clearly distinguishes between them. As seen in Fig. 2, b Fig. 3 to address the issue of agonistselective G protein regulation. These experiments examine the ligand saturation of CB 1 and CB 2 receptor activation of G␣ i or G␣ o with several distinct cannabinoid ligands. As shown in Fig. 3 , the efficacies of cannabinoid ligands are not only an intrinsic property of the cannabinoid receptor structure but also are dependent upon the G protein. Figure 3a presents data for the saturation of G␣ i activation by CB 1 receptors. Although displaying varying apparent affinities (Table 1) , HU210, WIN55,212, and anandamide were all equally efficacious for CB 1 catalyzed GDP-[
35 S]GTP␥S exchange on G␣ i . ⌬ 9 -THC displayed an efficacy of 57% compared with these three. In contrast to the data for G␣ i , anandamide, WIN55,212, and ⌬ 9 -THC were all partial agonists and only HU210 stimulated maximal GDP-[ 35 S]GTP␥S exchange for G␣ o . The observed efficacies for these agonist ligands were as follows: anandamide (71%), WIN55,212 (72%), and ⌬ 9 -THC (64%) compared with HU210 ( Fig. 3b ; Table 1) . For all the agonists tested with both G proteins the Hill coefficients for the interaction approximated 1 (data not shown) and the saturation data were well fit by a single-site model.
The ligand saturation of CB 2 receptor activation of G␣ i is shown in Fig. 3c . Because of the low apparent affinity and a doubtful physiological relevance of G␣ o for CB 2 , this receptor was examined only with G␣ i . Consistent with published K d values (Pertwee, 1997) , EC 50 values for ⌬ 9 -THC, anandamide, and HU210 were similar to those seen for CB 1 receptors, whereas WIN55,212 demonstrated a significantly higher potency at CB 2 receptors than at CB 1 receptors. As for G␣ i activation by CB 1 receptors, ⌬ 9 -THC was again a partial agonist for CB 2 (42%). Distinct from the CB 1 receptor, anandamide efficacy was equivalent to ⌬ 9 -THC for CB 2 (45%), whereas WIN55,212 induced a rate of G␣ i activation that was intermediate between ⌬ 9 -THC and HU210 ( Fig. 3c ; Table 1 ). The Hill coefficient of all the agonist response curves approximated 1 (data not shown).
Several lines of evidence argue that these differences in agonist efficacies are accurately measured in our studies. No difference was observed in the ability of anandamide to stimulate receptor-G protein coupling in the presence or absence of 4-(2-aminoethyl)benzenesulfonyl fluoride (data not shown), suggesting that amido-hydrolase enzymes do not survive the urea washing of the membranes. For both CB 1 and CB 2 receptors the activation of G␣ i and G␣ o increased with higher receptor concentrations (data not shown), indicating that these assays are limited by receptor. These results argue that the maximal stimulation of GDP-[ 35 S]GTP␥S exchange produced by each ligand must be directly proportional to its intrinsic efficacy.
Inverse Agonism of SR141716A at CB 1 Receptor. The inhibition of the CB 1 receptor by SR141716A has been reported for a number of intact cell models (Bouaboula et al., 1997; MacLennan et al., 1998; Pan et al., 1998) . Our in situ reconstitution allows the elimination of alternative cellular pathways or the existence of autocoid ligands as possible explanations for this phenomenon. To test for inverse agonism of SR141716A at the CB 1 receptor assay conditions were altered from those used for agonist stimulation to enable a greater rate of spontaneous activity of the receptor-G protein complex. In the presence of 5 mM Mg 2ϩ CB 1 recep- ]GTP␥S binding to levels equivalent to the additive total of membrane and G protein activity (Fig. 4) , thus confirming that this competitive antagonist is indeed an inverse agonist of the CB 1 receptor.
Discussion
A variety of important receptor types is thought to signal through pertussis toxin-sensitive pathways, and physiological studies of ion channel and cAMP regulation have suggested that a single receptor type may couple to multiple distinct pertussis toxin-substrate-G protein ␣-subunits (Gudermann et al., 1997). The cannabinoid receptors are of particular interest in this regard because the various pharmacological actions of cannabinoids may be linked to distinct intracellular pathways and the development of therapeutically effective agents devoid of intoxicating properties would be welcome. Furthermore, synthetic cannabinoid ligands may bind to distinct surfaces of the CB 1 receptor (for review, see Howlett, 1998) . This has led to the speculation that these chemically disparate agonists may direct receptor activation of selective G proteins. We therefore modified an in situ reconstitution approach previously used to characterize the G q coupling of 5-HT 2C receptors (Hartman and Northup, molpharm.aspetjournals.org 1996), and the bombesin family of receptors (Jian et al., 1999) to examine the G protein coupling of recombinant CB 1 and CB 2 receptors. Our data demonstrate that this technique can be applied successfully to other families of G proteins, including G i and G o proteins that have high rates of spontaneous GDP dissociation.
As predicted by signal transduction, studies CB 1 and CB 2 receptors did indeed show different abilities to activate the G proteins. Furthermore, the ability to recognize G proteins was selective because nonappropriate G proteins such as G q and G t were not recognized by either receptor. Both CB 1 and CB 2 receptors could activate G i with similar apparent affinity. In contrast to G i , the abilities of CB 1 and CB 2 receptors to activate G o protein were substantially different. Both receptors showed a lower apparent affinity for G o than for G i . However, the apparent affinity for the CB 2 receptor was too low to be measured accurately within the detergent constraints of this assay and was estimated to be at least 3-to 4-fold lower than that measured for CB 1 receptor activation of G o . This finding is consistent with the regional distribution of the cannabinoid receptors and G proteins. CB 1 receptors are localized to the brain and a few peripheral organs (Pertwee, 1997), whereas CB 2 receptor are localized primarily to immune cells. Conversely, although G i and G o are both neuronally localized, G i has been demonstrated to be present in immune cells, whereas G o is not abundant peripherally, suggesting that physiologically G i is likely to be the G protein encountered by CB 2 . Furthermore, this finding helps to explain the differences in signal transduction pathways observed for these receptors. The failure of CB 2 receptors to modulate ion channels may be explained by their low affinity for G o . Inhibition of voltage gated Ca 2ϩ channels is probably mediated via G␣ o , whereas activation of K ϩ channels is probably via ␤␥-subunits derived from either G i or G o (Gudermann et al., 1997) . It is also possible that ␤␥-subunits of differing composition have higher affinity for G o versus G i (or CB 1 versus CB 2 ), and that these subunits differentiate the ability of cannabinoid receptors to activate K ϩ channels. This data would suggest that CB 1 receptor coupling to ion channels is G o mediated, and that the lower apparent affinity of CB 2 for this G protein is sufficient to prevent regulation of ion channels.
The efficacy of a range of agonists to stimulate G i via the CB 2 receptors observed in this study correlated well with the existing signal transduction data for these receptors. In this study, HU210 was a full agonist, whereas WIN55,212, ⌬ 9 -THC, and anandamide were only partial agonists, although the degree of stimulation differed between the agonists with WIN55,212 producing an intermediate level of activation. Previous studies on the ability of cannabinoids to inhibit cAMP formation in cells transfected with CB 2 receptors have produced inconsistent results. Although Felder et al. (1995) found both ⌬ 9 -THC and anandamide to be inhibitory in CB 2 -transfected Chinese hamster ovary (CHO) cells, other investigators have reported either or both of these agents to have little or no inhibitory effect on cAMP production by CHO or COS-7 cells (Bayewitch et al., 1995 (Bayewitch et al., , 1996 Slipetz et al., 1995) . Only one study appears to have compared the abilities of HU210 and WIN55,212 to inhibit cAMP formation in CB 2 -transfected CHO cells (Slipetz et al., 1995) . That study found the maximal inhibition induced by these two compounds to be equivalent. This finding suggests that the receptor num- (Sim et al., 1995; Burkey et al., 1997a,b; Griffin et al., 1998) . Anandamide also produced partial agonism at G o in our study and has previously demonstrated submaximal activation of [
35 S]GTP␥S in cerebellar and whole-brain homogenates (Burkey et al., 1997a; Griffin et al., 1998; Kearn et al., 1999) . In contrast, WIN55,212 has been demonstrated to produce maximal GTP␥S 35 stimulation in the former studies. This difference most likely reflects the inability of the homogenate [
35 S]GTP␥S-binding assays to detect differences between different G proteins. Our data clearly demonstrate that one ligand can induce a receptor conformation that is maximally active in stimulating one G protein, whereas only partially active in its ability to activate a different G protein.
Thus, HU210 stabilizes a conformation of the CB 1 receptor that can fully activate both G i and G o . However, WIN55,212 must induce a different conformation, as it was a full agonist at the CB 1 receptor for activation of G i , but was only a partial for the activation of G o . This finding clearly suggests that ligands may be designed that are fully selective for one G protein pathway over another. Therapeutically, this could provide a powerful mechanism for selecting for particular actions of cannabinoids, while avoiding some of the unwanted effects.
That different agonists might induce different conformations of the CB 1 receptor is not entirely unpredicted given that the agonists are known to bind differentially to the receptor. WIN55,212 belongs to the nonclassical class of cannabinoids, the aminoalkylindoles. Although classical cannabinoids and aminoalkylindoles agonists show competitive binding interactions at the CB 1 receptor and appear to exhibit some pharmacophoric elements in common (for review, see Howlett, 1998) , it appears that their interaction with the cannabinoid receptor is not identical. Mutation studies of the CB 1 receptor have identified at least one point of receptor interaction with cannabinoid ligands, a predicted helix III lysine, that inhibits binding of anandamide and CP55,940 [(Ϫ)-cis-3-[2-hydroxy-4-(1-1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol], but has no effect on the binding of aminoalkylindole ligands (Song and Bonner, 1996; Chin et al., 1998) . It is possible that the different points of ligand-receptor interaction promote different receptor conformations, which in turn result in selective interaction with different G proteins. Although much work has been carried out on the sites of interaction of receptors with G proteins (for review, see Gudermann et al., 1997) , it is still unclear whether contact sites for different G proteins on cytoplasmic receptor parts can be differentiated or are identical. Previous studies on a range of receptor types have suggested that this "agonist trafficking" of signaling pathways is possible (Tucek, 1997) . However, these studies have focused on the activation of second messenger pathways, rather than directly measuring G protein activation. A recent study has demonstrated WIN55,212 to be more efficacious than other agonists tested in stimulating cAMP accumulation in CHO cells expressing the CB 1 receptor following pertussis toxin treatment . Previous studies have suggested that this pathway may be mediated by G␣ s (Glass and Felder, 1997) , suggesting that agonist-receptor complexes may differ in their recognition of G s in addition to G i and G o .
Several previous reports have suggested that the CB 1 receptor antagonists SR141716A may exhibit inverse agonist properties (Bouaboula et al., 1997; MacLennan et al., 1998; Pan et al., 1998) . Inverse agonism differs from conventional antagonism, in that rather than possessing equivalent affinity for both the active and inactive receptor states, inverse agonists have a higher affinity for the inactive state, thereby inhibiting any spontaneous activity of the receptor. SR141716A also has been reported to reduce basal GTP␥S binding in membranes from cells with CB 1 receptors (Landsman et al., 1997) . However, other studies have failed to observe this effect (Breivogel et al., 1998; Kearn et al., 1999) . Recently, Pan et al. (1998) demonstrated constitutive activity of CB 1 receptors in inhibiting Ca 2ϩ currents that was not due to endogenous agonist, confirming that CB 1 receptors can be tonically active. In our study, CB 1 receptors exhibited spontaneous activation of both G i and G o that could be enhanced by additional magnesium. This spontaneous activity was completely blocked by SR141716A, indicative of strong inverse agonism. It is tempting to speculate based on our findings with cannabinoid agonists that inverse agonists also may be capable of distinguishing between G proteins.
The physiological relevance of the difference in the ability of ligands to regulate G protein signaling will depend on a combination of the number of receptors in the cell, and the saturation properties of the effector molecules. Thus, if saturation of the second messenger response (e.g., inhibition of adenylate cyclase, enhancement of potassium conductance) requires full stimulation of G protein, then partial efficacy would be visible if receptor number was limited. If, however, the maximal response can be generated by submaximal G protein activation, then the difference between agonists may not be readily discernable. This model, therefore, provides a mechanism for explaining the differences observed in potency of agonists in different tissues or cells. For example, Mackie et al., (1993) demonstrated that anandamide was a partial agonist in the inhibition of calcium channels in N18 neuroblastoma cells, but they observed full agonism of this effect in AtT20 cells that express higher receptor number . Our studies have demonstrated that anandamide is a partial agonist in the activation of G␣ o , the G protein thought to mediate calcium channel activation. Thus, these findings are consistent that when receptor is limited, the differences in response to particular agonists become detectable. This finding emphasizes the importance of future studies focused on designing agonists that more fully distinguish between different G proteins. The ability of the cannabinoid receptors to activate G proteins in the absence of agonist confirms that the cannabinoid signaling may have an intrinsic tone independent of cell activity. Previous studies with 5-HT receptors have demonstrated that not all antagonists can act as inverse agonists (Hartman and Northup, 1996) . This would suggest that the physiological response of a pure antagonist will differ from an inverse agonist, again increasing the range of potential therapeutic outcomes mediated through the cannabinoid receptors. Furthermore, this study demonstrates reconstitution as an ideal system for screening potential antagonists, inverse agonists, and subclasses of agonists.
